IRIS
MENNINI, FRANCESCO SAVERIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.847
EU - Europa 3.353
AS - Asia 1.386
SA - Sud America 24
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 5
Totale 31.634
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.802
IT - Italia 1.442
SG - Singapore 755
IE - Irlanda 467
DE - Germania 324
UA - Ucraina 307
CN - Cina 304
RU - Federazione Russa 212
GB - Regno Unito 143
SE - Svezia 128
FR - Francia 122
VN - Vietnam 96
KR - Corea 91
FI - Finlandia 62
CA - Canada 38
IR - Iran 29
IN - India 28
BE - Belgio 26
CH - Svizzera 23
NL - Olanda 23
PL - Polonia 22
HK - Hong Kong 18
TW - Taiwan 16
ES - Italia 13
BR - Brasile 12
JP - Giappone 10
PK - Pakistan 10
EU - Europa 9
PT - Portogallo 8
CO - Colombia 6
CZ - Repubblica Ceca 6
RO - Romania 6
AT - Austria 5
IQ - Iraq 5
ZA - Sudafrica 5
AU - Australia 4
MY - Malesia 4
PH - Filippine 4
BD - Bangladesh 3
DK - Danimarca 3
DM - Dominica 3
GR - Grecia 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
CL - Cile 2
HT - Haiti 2
HU - Ungheria 2
ID - Indonesia 2
MK - Macedonia 2
TH - Thailandia 2
TR - Turchia 2
ZM - Zambia 2
BO - Bolivia 1
CU - Cuba 1
GH - Ghana 1
HR - Croazia 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MU - Mauritius 1
MX - Messico 1
NA - Namibia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
SA - Arabia Saudita 1
SI - Slovenia 1
UZ - Uzbekistan 1
Totale 31.634
Salva come PNG Salva come JPEG
Città #
Wilmington 7.328
Houston 6.965
Woodbridge 6.868
Fairfield 909
Singapore 657
Chandler 510
Ann Arbor 429
Ashburn 392
Dublin 390
Seattle 340
Medford 298
Cambridge 294
Rome 287
Jacksonville 263
New York 210
Dearborn 185
Beijing 161
Milan 160
Santa Clara 158
Lawrence 138
Dong Ket 94
San Diego 85
Menlo Park 59
Moscow 55
Phoenix 34
Redwood City 28
Verona 27
Catania 26
Mülheim 26
Seoul 26
London 25
Nanjing 22
Brussels 21
Turin 21
Toronto 19
Florence 18
Norwalk 18
Napoli 17
Parma 16
Hangzhou 15
Hong Kong 15
Kraków 15
Guangzhou 14
Naples 14
Boardman 13
Creede 12
Falls Church 12
Messina 12
Zurich 12
Monmouth Junction 11
Munich 11
Ottawa 11
Perugia 11
Taipei 11
University Park 11
Mountain View 10
Bologna 9
Kunming 9
Zhengzhou 9
Bangalore 8
Chengdu 8
Dallas 8
Frankfurt am Main 8
Hefei 8
Redmond 8
Saint Petersburg 8
San Francisco 8
San Mateo 8
Tehran 8
Genoa 7
Lisbon 7
Los Angeles 7
Miami 7
Palermo 7
Pomezia 7
Rho 7
Amsterdam 6
Brescia 6
Helsinki 6
Roebling 6
Shanghai 6
São Paulo 6
Bari 5
Campobasso 5
Cattolica 5
Charsadda 5
Duncan 5
Galway 5
Genova 5
Jinan 5
Locate Varesino 5
Madrid 5
Padova 5
Scandicci 5
Spoltore 5
Trento 5
Washington 5
Andover 4
Catanzaro 4
Ciciliano 4
Totale 28.068
Salva come PNG Salva come JPEG
Nome #
Extending influenza vaccination to individuals aged 50-64: a budget impact analysis 508
Strategie e performance nel mercato farmaceutico italiano: un'analisi empirica 491
Economic Burden of Human Papillomavirus-Related Diseases in Italy 438
General disease costing principles 437
Economic effects of treatment of chronic kidney disease with low-protein diet 430
Governance of preventive health intervention and on time verification of its efficiency: the GIOVE study 425
A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache 423
Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group 423
A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache 407
Rapporto CEIS-Sanità 2006: il governo del sistema sanitario: complessità e prospettive dei nuovi assetti istituzionali 402
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. 402
The perception of corruption in health: AutoCM methods for an international comparison 400
Rapid responses to: Letter to the Editor, by L. Garattini and G. Casadei [Vaccine 27 (38) (20 August 2009) 5171] 399
Scenari e strategie nel settore farmaceutico 399
Cost-effectiveness analysis for the treatment of chronic kidney disease with low-protein diet 396
Towards the eradication of HPV infection through universal specific vaccination 389
Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 386
Hospital costs incurred by the Italian national health service for invasive cervical cancer 382
The new perspectives of italian national health service 382
A One-Year Economic Evaluation of Botulinum Toxin Type A Treatment of Chronic Tension-type Headaches: Part II 381
Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline 380
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 378
Improving care through health economics analyses: cost of illness and headache 375
Health and economic impact associated with a quadrivalent HPV vaccine in Italy 375
Pilot evaluation of indirect costs and the impact of bipolar disorder type I 372
Rapporto CEIS-Sanità 2005: sette parole chiave del SSN 370
Oral vs injection therapy in the treatment of metastatic colorectal cancer. a cost minimization analysis in a public hospital of the lazio region [Terapia orale vs terapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato analisi di minimizzazione dei costi presso una struttura ospedaliera della regione lazio] 370
Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study 364
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 359
Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study 356
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy 356
Rapporto CEIS-Sanità 2004: sostenibilità, equità e ricerca dell'efficienza 354
Public health value of universal HPV vaccination 354
Rapporto CEIS-Sanità 2003: bisogni, risorse e nuove strategie 352
Cost of poor adherence to anti-hypertensive therapy in five European countries 348
Rapporto CEIS-Sanità 2007: responsabilità, autonomia, sussidiarietà, integrazione, valutazione, empowerment: 6 "nuove" parole chiave per il futuro del SSN 346
Economic evaluation of spondyloarthritis: Economic impact of diagnostic delay in Italy 338
The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. 338
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis 335
The Welfare States in a United Europe 332
Improving care through health economics analyses: cost of illness and headache (general disease costing principles) 329
Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients 329
Anti-HPV vaccination in Italy: a review of recent economic data for Italy 327
Equità e fairness del servizio sanitario nazionale italiano 326
The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation 326
Joint Procurement and the EU perspective. In Law and Economics of Public Procurement reforms 324
The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports. 323
Criteri per l'allocazione regionale delle risorse per la sanità: riflessioni sul caso italiano 322
Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries?: An approach based on Artificial Neural Networks 318
Primary Biliary Cholangitis: advances in management and treatment of the disease 317
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study 316
Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study 315
Il settore industriale sanitario in Italia 314
Dinamiche e determinanti del settore farmaceutico in Europa 310
Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. [Costi diretti e indiretti associati a malattie allergiche respiratorie in Italia. Uno studio probabilistico di cost of illness] 303
Human papillomavirus 9-valent vaccine for cancer prevention: A systematic review of the available evidence 302
Time trade-off procedure for measuring health utilities loss with human papillomavirus–induced diseases: a multicenter, retrospective, observational pilot study in Italy 300
Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region 296
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada 294
Fraud and Corruption in Healthcare: Recognizing Such Phenomena to Combat Them. 286
Health policy model: Long-term Predictive results associated with the management of hepatitis C virus-induced diseases in Italy 284
Dimensioni e tendenze del mercato farmaceutico in Italia (1980/1997) 283
PDB51. Direct and indirect cost of diabetes in italy: A prevalence probabilistic approach 281
A novel method to value real options in health care: The case of a multicohort human papillomavirus vaccination strategy 281
Il settore industriale farmaceutico italiano 275
Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanerceptt 272
null 263
Early treatment in HIV patients: a cost–utility analysis from the Italian perspective 257
Economics of Headache 255
Introduzione 254
Analisi di impatto di budget di pasireotide in pazienti con Acromegalia nella prospettiva del Servizio Sanitario Nazionale 254
Strategie e performance delle grandi aziende farmaceutiche in Italia (1979-2001) 253
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 237
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy 231
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 220
The economic impact of biosimilars in Italy: a scenario analysis 216
Erratum to: Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 215
Screening strategies for Hepatitis C Virus elimination in Italy 211
Economic burden of HPV9-related diseases: a real-world cost analysis from Italy 205
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer 202
Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. Human menopausal gonadotropin for women undergoing IVF 201
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma 198
Using real-world data to estimate the Social Security Costs of Retinal Diseases: Results from the Observatory on Legal Blindness 194
Budget Impact Analysis della gestione dell'agitazione psicomotoria con loxapina inalatoria in Italia. 183
HPV Vaccination Concepts in the Reality of Today 182
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy 180
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of 3 European Countries 176
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 169
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group 154
Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy 153
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto 148
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries 147
PIN79 - ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE: A REAL-WORLD-BASED ANALYSIS FROM PITER DATA 142
Economic Consequences of Anti-HCV Antiviral Treatment Investment from the NHS Perspective 142
. The burden of atopic dermatitis in adults in Italy 138
La corruzione in sanità: i nuovi strumenti per individuarla e contrastarla 138
Estimation of the number of HCV-positive patients in Italy 137
Invecchiamento della popolazione e sostenibilità del SSN:il ruolo della Health Technology Assessment (HTA) per la valutazione tecnica, economica ed organizzativa della Sanità del futuro 137
Burden economico della neuropatia ottica ereditaria di Leber (LHON) in Italia: stima dei costi indiretti e diretti a carico del paziente. 125
The burden of atopic dermatitis in adults in Italy 124
Totale 29.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.480
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.480
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.814 0 0 0 0 795 887 750 736 860 686 573 527
2020/20215.494 521 537 631 569 760 621 640 500 147 145 241 182
2021/20221.610 77 131 140 88 71 88 149 143 95 84 149 395
2022/20231.734 178 113 51 201 154 407 165 109 148 33 120 55
2023/2024966 89 44 69 33 80 233 66 50 63 52 46 141
2024/20251.622 117 839 351 232 83 0 0 0 0 0 0 0
Totale 32.083